Dr. Gupta discusses bladder cancer research highlights from ASCO 2021

Roger Li, MD, Moffit Cancer Center, was awarded the grant to study the novel oncolytic virus drug CG0070 in patients with intermediate-risk non–muscle-invasive bladder cancer.

Laura Bukavina, MD, and Kyle Rose, MD, discuss some of the notable abstracts from the 2023 ASCO GU conference.

“There is an urgent need for new treatment options for [patients with] urothelial carcinoma, many of whom find themselves out of options after progressing on immune checkpoint inhibitors," said Sergio Santillana, MD.

“Obviously, patients benefit [from this regimen]. Not only can they enjoy longer life, but also their cancer is pretty much under control for a longer time, which is great,” says Karim Fizazi, MD, PhD

"These findings may directly inform clinical care, such as providing diet recommendations for managing health, and potentially offer other positive health benefits for preventing numerous chronic diseases,” said Bradley Alexander McGregor, MD.

"The Medicaid and uninsured patients had significantly lower odds of getting treatment than those who [have] private insurance," says Madison Novosel, BA.